Societal costs and health related quality of life in adult atopic dermatitis

被引:7
作者
Beretzky, Zsuzsanna [1 ]
Koszoru, Kamilla [2 ]
Rencz, Fanni [1 ]
Hajdu, Krisztina [3 ,4 ]
Borza, Julia [2 ]
Bodai, Katalin [5 ]
Xu, Feifei [1 ]
Szegedi, Andrea [3 ,4 ]
Sardy, Miklos [2 ]
Brodszky, Valentin [1 ]
机构
[1] Corvinus Univ Budapest, Dept Hlth Policy, 8 Fovam Ter, H-1093 Budapest, Hungary
[2] Semmelweis Univ, Fac Med, Dept Dermatol Venereol & Dermatooncol, Budapest, Hungary
[3] Univ Debrecen, Fac Med, Dept Dermatol, Debrecen, Hungary
[4] Ctr Excellence MTA & ELKH DE Allergol Res Grp, Debrecen, Hungary
[5] St Martin Outpatient Ctr, Pannonhalma, Hungary
关键词
Atopic dermatitis; Dermatology; Cost; Disease burden; DLQI; EQ-5D; SEVERITY INDEX EASI; ECZEMA AREA; BURDEN; PRODUCTIVITY; EPIDEMIOLOGY;
D O I
10.1186/s12913-023-09840-7
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BackgroundCost-of-illness studies are widely used for healthcare decision-making in chronic conditions. Our aim was to assess the cost-of-illness of adult atopic dermatitis (AD) from the societal perspective in Hungary.MethodsWe conducted a multicentre, cross-sectional questionnaire survey between February 2018 and January 2021. Data was collected from consecutive AD patients aged & GE; 18 years and their physicians at dermatology departments in Hungary. We calculated direct and indirect costs, including costs for treatments, outpatient visits, hospital admissions, informal care, travel costs and productivity loss. To assess indirect costs, the Work Productivity and Activity Impairment (WPAI) questionnaire was used to collect data, and costs were estimated with the human capital approach. Generalized linear model was used to analyse predictors of total, direct and indirect costs.ResultsAltogether 218 patients completed the survey (57.8% female) with an average age of 31.3 (SD = 11.7). Patients' average Dermatology Life Quality Index (DLQI) score was 13.5 (SD = 8.5). According to Eczema Area and Severity Index (EASI) score, 2.3% (n = 5), 21.2% (n = 46), 54.4% (n = 118) and 22.1% (n = 48) had clear, mild, moderate, and severe AD, respectively. We found that the average total, direct medical, direct non-medical and indirect annual costs per patients were euro4,331, euro1,136, euro747, and euro2450, respectively, with absenteeism and presenteeism being the main cost drivers, accounting for 24% and 29% of the total cost of AD. A one-year longer disease duration led to, on average, 1.6%, and 4.2% increase in total and direct non-medical costs, respectively. Patients with worse health-related quality of life (higher DLQI score) had significantly higher total, direct medical, direct non-medical costs, and indirect costs.ConclusionsOur results indicate a substantial economic burden of AD from a societal perspective, mainly driven by productivity losses.
引用
收藏
页数:10
相关论文
共 49 条
[11]   Atopic dermatitis: Burden of illness, quality of life, and associated complications [J].
Drucker, Aaron M. .
ALLERGY AND ASTHMA PROCEEDINGS, 2017, 38 (01) :3-8
[12]   The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association [J].
Drucker, Aaron M. ;
Wang, Annie R. ;
Li, Wen-Qing ;
Sevetson, Erika ;
Block, Julie K. ;
Qureshi, Abrar A. .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (01) :26-30
[13]   Considering the societal perspective in economic evaluations: a systematic review in the case of depression [J].
Duevel, Juliane Andrea ;
Hasemann, Lena ;
Pena-Longobardo, Luz Maria ;
Rodriguez-Sanchez, Beatriz ;
Aranda-Reneo, Isaac ;
Oliva-Moreno, Juan ;
Lopez-Bastida, Julio ;
Greiner, Wolfgang .
HEALTH ECONOMICS REVIEW, 2020, 10 (01)
[14]   Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: An analysis using the National Health and Wellness Survey [J].
Eckert, Laurent ;
Gupta, Shaloo ;
Amand, Caroline ;
Gadkari, Abhijit ;
Mahajan, Puneet ;
Gelfand, Joel M. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (02) :274-+
[15]   The Multidimensional Burden of Atopic Dermatitis Among Adults Results From a Large National Survey [J].
Elsawi, Rawaan ;
Dainty, Katie ;
Begolka, Wendy Smith ;
Barta, Kelly ;
Butler, Lisa ;
Capozza, Korey ;
Eftekhari, Sanaz ;
Tullos, Kathryn Z. ;
Wu, Wei ;
Drucker, Aaron M. .
JAMA DERMATOLOGY, 2022, 158 (08) :887-892
[16]  
European Medicines Agency (EMA), 2012, Velsipity Assessment Report
[17]   Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study [J].
Gaspar, Krisztian ;
Gergely, L. Hunor ;
Jenei, Balazs ;
Wikonkal, Norbert ;
Kinyo, Agnes ;
Szegedi, Andrea ;
Remenyik, Eva ;
Kiss, Norbert ;
Jin, Xiang ;
Sardy, Miklos ;
Beretzky, Zsuzsanna ;
Pentek, Marta ;
Gulacsi, Laszlo ;
Banvolgyi, Andras ;
Brodszky, Valentin ;
Rencz, Fanni .
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (03) :399-408
[18]   Validity of EQ-5D-5L, Skindex-16, DLQI and DLQI-R in patients with hidradenitis suppurativa [J].
Gergely, L. H. ;
Gaspar, K. ;
Brodszky, V ;
Kinyo, A. ;
Szegedi, A. ;
Remenyik, E. ;
Kiss, N. F. ;
Bato, A. ;
Pentek, M. ;
Gulacsi, L. ;
Sardy, M. ;
Banvolgyi, A. ;
Wikonkal, N. ;
Rencz, F. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (11) :2584-2592
[19]   The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis [J].
Hanifin, JM ;
Thurston, M ;
Omoto, M ;
Cherill, R ;
Tofte, SJ ;
Graeber, M .
EXPERIMENTAL DERMATOLOGY, 2001, 10 (01) :11-18
[20]  
Harangi F., 2010, EG SZS G AKAD MIA, V1, P37